|
|
News Breaks | | | | September 25, 2012 | | 07:03 EDT |  | ATRS | Antares Pharma announces positive result for MTX study
Antares Pharma announced positive results from an Actual Human Use, or AHU, study for VIBEX Methotrexate, or MTX. The clinical trial was conducted as a multi-center, open-label, single-arm, in-clinic study to evaluate the actual human use of methotrexate administered via the VIBEX Medi- Jet in adult patients with rheumatoid arthritis. The study assessed the safe usability of VIBEX MTX for self-administration of parenteral MTX in adult RA patients after standardized training by site personnel and review of written instructions. Secondary objectives included evaluation of the reliability, ease of use and robustness of the VIBEX Medi-Jet; assess the safety and local tolerance of Medi-Jet administered MTX and to evaluate the effectiveness of the patient education tools including written instructions for use. | |
|
News For ATRS From The Last 14 Days Check below for free stories on ATRS the last two weeks. |
|
|
| June 13, 2013 | | 07:05 EDT | | ATRS | Antares Pharma's auto-injection device shows positive results in clinical study
Antares Pharma announced clinical study results demonstrating that subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the treatment of adults with rheumatoid arthritis. The self-administration device is one component of an investigational product under review by the FDA that combines the company's proprietary Vibex auto-injection delivery device with an injectable version of methotrexate, the drug long regarded as the standard of care in the treatment of rheumatoid arthritis. | |
|
|
|
|
|
|
